Abstract
Helicobacter pylori colonize stomach, inducing gastritis, ulcers and gastric cancer. Drugs are used to relieve pain, but not H. pylori infections. Hence, there is a need for discovery of drug targets and drugs for H. pylori. An objective of this current study is to identify drug targets for H. pylori. RAST was used to compare genomes of 23 H. pylori strains with Homo sapiens sapiens, other Helicobacter species (H. acinonychis, H. hepaticus, H. mustalae) and among them, to identify 13471 unique genes. Bacterial genes which are non-homologous to humans and essential for pathogen are identified using BLASTp. Later, 29 potential drug targets were identified by subjecting these genes to property analysis. Eleven of the 29 drug targets are already experimentally validated, lending credence to our approach. These methods have enabled rapid identification of drug targets with possible therapeutic implications for gastric cancer.
Keywords: Drug targets, genome analysis, host-pathogen comparison, proteome comparison, strain-strain comparison, speciesspecies comparison.
Graphical Abstract
Current Cancer Drug Targets
Title:Identification of Drug Targets in Helicobacter pylori by in silico Analysis : Possible Therapeutic Implications for Gastric cancer
Volume: 16 Issue: 1
Author(s): Deepthi Nammi, Ravi C. P. K. Srimath-Tirumala-Peddinti and Nageswara Rao R. Neelapu
Affiliation:
Keywords: Drug targets, genome analysis, host-pathogen comparison, proteome comparison, strain-strain comparison, speciesspecies comparison.
Abstract: Helicobacter pylori colonize stomach, inducing gastritis, ulcers and gastric cancer. Drugs are used to relieve pain, but not H. pylori infections. Hence, there is a need for discovery of drug targets and drugs for H. pylori. An objective of this current study is to identify drug targets for H. pylori. RAST was used to compare genomes of 23 H. pylori strains with Homo sapiens sapiens, other Helicobacter species (H. acinonychis, H. hepaticus, H. mustalae) and among them, to identify 13471 unique genes. Bacterial genes which are non-homologous to humans and essential for pathogen are identified using BLASTp. Later, 29 potential drug targets were identified by subjecting these genes to property analysis. Eleven of the 29 drug targets are already experimentally validated, lending credence to our approach. These methods have enabled rapid identification of drug targets with possible therapeutic implications for gastric cancer.
Export Options
About this article
Cite this article as:
Nammi Deepthi, Srimath-Tirumala-Peddinti C. P. K. Ravi and Neelapu Rao R. Nageswara, Identification of Drug Targets in Helicobacter pylori by in silico Analysis : Possible Therapeutic Implications for Gastric cancer, Current Cancer Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1568009615666150602143239
DOI https://dx.doi.org/10.2174/1568009615666150602143239 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Solubility and Permeability Measurement and Applications in Drug Discovery
Combinatorial Chemistry & High Throughput Screening Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Characterization of Probiotic Lactobacillus plantarum MYS14 Isolated from Sannas, a Traditional Fermented Food for its Therapeutic Potential
Current Nutrition & Food Science Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Endoplasmic Reticulum Stress Inhibition Enhances Liver Tolerance to Ischemia/Reperfusion
Current Medicinal Chemistry Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Colloidal Carrier Systems for Transcutaneous Immunization
Current Drug Targets The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy
Current Topics in Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications
Current Pharmaceutical Design Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) MicroRNAs in Human Virus Genomes: Helping Hands for Viral Infection
MicroRNA Mechanisms of Trastuzumab Resistance in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Evidence for Anti-Cancer Properties of Blueberries: A Mini-Review
Anti-Cancer Agents in Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses
Current Cancer Drug Targets